In functional dyspepsia, which statement is true regarding response to treatment?

In functional dyspepsia, which statement is true regarding response to treatment?

• A. Epigastric pain syndrome more likely to respond to a proton pump inhibitor.
• B. Epigastric pain syndrome more likely to respond to a motility agent.
• C. Postprandial distress syndrome responds better to antibiotics.
• D. Both subtypes respond equally to motility agents.

Answer: (A)

Functional dyspepsia consists of two subtypes with distinct therapeutic responses: epigastric pain syndrome (pain or burning in the epigastrium) and postprandial distress syndrome (postprandial fullness and early satiety). The epigastric pain syndrome pattern is more likely to be acid-related, so it tends to respond well to acid suppression with a proton pump inhibitor. In contrast, postprandial distress syndrome is more linked to impaired gastric accommodation and motility, so prokinetic or motility-targeted therapies are more helpful for that pattern. Therefore, the statement that epigastric pain syndrome is more likely to respond to a proton pump inhibitor is the best choice. The other statements are less consistent with these differing mechanisms: EPS is not primarily driven by motility issues, antibiotics are not a standard effective treatment for PDS, and motility agents do not produce equal benefit across both subtypes.

Functional dyspepsia consists of two subtypes with distinct therapeutic responses: epigastric pain syndrome (pain or burning in the epigastrium) and postprandial distress syndrome (postprandial fullness and early satiety). The epigastric pain syndrome pattern is more likely to be acid-related, so it tends to respond well to acid suppression with a proton pump inhibitor. In contrast, postprandial distress syndrome is more linked to impaired gastric accommodation and motility, so prokinetic or motility-targeted therapies are more helpful for that pattern. Therefore, the statement that epigastric pain syndrome is more likely to respond to a proton pump inhibitor is the best choice. The other statements are less consistent with these differing mechanisms: EPS is not primarily driven by motility issues, antibiotics are not a standard effective treatment for PDS, and motility agents do not produce equal benefit across both subtypes.